Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitor (ICI) therapy has proven effective for many cancer patients, but predicting which patients with renal cell carcinoma (RCC) will respond has been challenging. We analyzed clinical characteristics and molecular parameters of a cohort of patients with RCC tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiuan, Eileen, Reddy, Anupama, Dudzinski, Stephanie O., Lim, Aaron R., Sugiura, Ayaka, Hongo, Rachel, Young, Kirsten, Liu, Xian-De, Smith, Christof C., O’Neal, Jamye, Dahlman, Kimberly B., McAlister, Renee, Chen, Beiru, Ruma, Kristen, Roscoe, Nathan, Bender, Jehovana, Ward, Joolz, Kim, Ju Young, Vaupel, Christine, Bordeaux, Jennifer, Ganesan, Shridar, Mayer, Tina M., Riedlinger, Gregory M., Vincent, Benjamin G., Davis, Nancy B., Haake, Scott M., Rathmell, Jeffrey C., Jonasch, Eric, Rini, Brian I., Rathmell, W. Kimryn, Beckermann, Kathryn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004696/
https://www.ncbi.nlm.nih.gov/pubmed/33806963
http://dx.doi.org/10.3390/cancers13061475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004696/
https://www.ncbi.nlm.nih.gov/pubmed/33806963
http://dx.doi.org/10.3390/cancers13061475

Ejemplares similares